Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating ...

MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating head and neck squamous cell ...

Renibus has completed subject enrolment for the Phase III PROTECT trial of RBT-1 in minimising post-operative risk in cardiac ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

Tiziana Life Sciences has announced the commencement of dosing in the fourth clinical site of the company’s Phase II trial of ...

Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

Daiichi and AstraZeneca's Enhertu with pertuzumab has shown PFS improvement in the Phase III DESTINY-Breast09 trial.

Cellphire Therapeutics has stopped enrolling subjects in its CRYPTICS trial of CLPH-511 following feedback from an IDMC.

A Phase I/II trial by Japan’s Kyoto University Hospital and CiRA team has demonstrated outcomes with allogeneic iPS ...